================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-QSB
|X| Quarterly Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
For the quarterly period ended June 30, 2004; or
|_| Transition Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
For the transition period from __________ to __________
Commission file number: 0-12742
SPIRE CORPORATION
--------------------------------------------------------------------------------
(Name of small business issuer as specified in its charter)
MASSACHUSETTS 04-2457335
--------------------------------------------------------------------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification Number)
ONE PATRIOTS PARK
BEDFORD, MASSACHUSETTS 01730-2396
--------------------------------------------------------------------------------
(Address of principal executive offices)
781-275-6000
--------------------------------------------------------------------------------
(Issuer's telephone number)
Securities registered under Section 12(g) of the Act:
COMMON STOCK, $0.01 PAR VALUE; REGISTERED ON THE NASDAQ STOCK MARKET
--------------------------------------------------------------------
(Title of class)
Check whether the issuer: (1) filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12
months (or for such shorter period that the issuer was required to file such
reports); and (2) has been subject to such filing requirements for the past 90
days. Yes |X| No |_|
State the number of shares outstanding of each of the issuer's classes of
common equity, as of the latest practicable date. There were 6,836,409
outstanding shares of the issuer's only class of common equity, Common Stock,
$0.01 par value, on July 30, 2004.
Transitional Small Business Disclosure Format (check one): Yes |_| No |X|
================================================================================
TABLE OF CONTENTS
Page
----
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
Unaudited Condensed Consolidated Balance Sheet as of June 30, 2004.. 1
Unaudited Condensed Consolidated Statements of Operations
for the Three and Six Months Ended June 30, 2004 and 2003........... 2
Unaudited Condensed Consolidated Statements of Cash Flows
for the Six Months Ended June 30, 2004 and 2003 ................... 3
Notes to Unaudited Condensed Consolidated Financial Statements ..... 4
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations .........................................10
Item 3. Controls and Procedures ...........................................19
PART II. OTHER INFORMATION
Item 1. Legal Proceedings .................................................20
Item 2. Changes in Securities ............................................20
Item 3. Defaults Upon Senior Securities ...................................20
Item 4. Submission of Matters to a Vote of Security Holders ...............20
Item 5. Other Information .................................................21
Item 6. Exhibits and Reports on Form 8-K ..................................21
PART I
FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
SPIRE CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEET
(UNAUDITED)
JUNE 30, 2004
------------
ASSETS
Current assets
--------------
Cash and cash equivalents $ 5,348,654
Restricted cash 670,544
------------
6,019,198
Net accounts receivable, trade 4,144,368
Inventories 1,988,562
Refundable income taxes 329,400
Deferred income taxes 231,864
Prepaid expenses and other current assets 251,978
------------
Total current assets 12,965,370
------------
Property and equipment 23,805,778
Less: accumulated depreciation and amortization (15,931,786)
------------
Net property and equipment 7,873,992
------------
Deposit - related party 168,750
Intangible and other assets, net 693,081
------------
Total assets $ 21,701,193
============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
-------------------
Current portion of capital lease obligation $ 387,905
Current portion of capital lease obligation - related party 485,461
Accounts payable 1,297,410
Accrued liabilities 1,476,963
Current portion of accrued lease obligation - related party 504,596
Advances on contracts in progress 801,355
------------
Total current liabilities 4,953,690
------------
Long-term portion of capital lease obligation 651,029
Long-term portion of capital lease obligation - related party 2,545,695
Accrued lease obligation - related party 217,471
Deferred income taxes 147,864
Unearned purchase discount 1,355,981
------------
Total long-term liabilities 4,918,040
------------
Total liabilities 9,871,730
------------
Commitments and Contingencies:
------------------------------
Stockholders' equity
--------------------
Common stock, $0.01 par value; shares authorized 20,000,000;
issued 6,827,909 shares in 2004 68,279
Additional paid-in capital 9,390,357
Retained earnings 2,370,827
------------
Total stockholders' equity 11,829,463
------------
Total liabilities and stockholders' equity $ 21,701,193
============
See accompanying notes to condensed consolidated financial statements.
1
SPIRE CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30,
------------------------------ ------------------------------
2004 2003 2004 2003
------------ ------------ ------------ ------------
Net sales and revenues
----------------------
Contract research and service revenues $ 2,748,874 $ 1,926,619 $ 5,331,062 $ 3,518,684
Sales of goods 1,508,991 1,828,302 3,957,069 3,195,330
------------ ------------ ------------ ------------
Total sales and revenues 4,257,865 3,754,921 9,288,131 6,714,014
------------ ------------ ------------ ------------
Costs and expenses
------------------
Cost of contract research and services 2,113,125 1,255,908 4,119,373 2,255,218
Cost of goods sold 1,388,027 1,722,059 3,308,604 3,009,816
Selling, general and administrative expenses 2,030,134 1,525,064 4,088,956 2,882,131
Internal research and development 377,340 283,248 730,625 379,345
------------ ------------ ------------ ------------
Total costs and expenses 5,908,626 4,786,279 12,247,558 8,526,510
------------ ------------ ------------ ------------
Gain on sale of license 3,000,000 4,989,150 3,000,000 4,989,150
------------ ------------ ------------ ------------
Earnings from operations 1,349,239 3,957,792 40,573 3,176,654
------------------------
Interest expense, net (70,529) (21,512) (139,918) (14,083)
------------ ------------ ------------ ------------
Earnings (loss) before income taxes 1,278,710 3,936,280 (99,345) 3,162,571
Income tax expense -- 675,000 -- 675,000
------------ ------------ ------------ ------------
Net earnings (loss) $ 1,278,710 $ 3,261,280 $ (99,345) $ 2,487,571
------------------- ============ ============ ============ ============
Earnings (loss) per share of common stock - basic $ 0.19 $ 0.48 $ (0.01) $ 0.37
------------------------------------------------- ============ ============ ============ ============
Earnings (loss) per share of common stock - diluted $ 0.18 $ 0.48 $ (0.01) $ 0.37
--------------------------------------------------- ============ ============ ============ ============
Weighted average number of common and common
equivalent shares outstanding - basic 6,789,206 6,761,660 6,777,368 6,759,127
============ ============ ============ ============
Weighted average number of common and common
equivalent shares outstanding - diluted 7,062,623 6,804,403 6,777,368 6,788,146
============ ============ ============ ============
See accompanying notes to condensed consolidated financial statements.
2
SPIRE CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
SIX MONTHS ENDED JUNE 30,
------------------------------
2004 2003
------------ ------------
Cash flows from operating activities:
-------------------------------------
Net income (loss) $ (99,345) $ 2,487,571
Adjustments to reconcile net income (loss) to net cash used
in operating activities:
Depreciation and amortization 1,244,451 483,356
Gain on sale of license (3,000,000) (4,989,150)
Changes in assets and liabilities (excluding business
acquisition):
Restricted cash (7,655) (102,857)
Accounts receivable, net 95,969 1,152,869
Inventories (557,573) 442,899
Prepaid expenses and other current assets 142,355 213,503
Refundable income taxes 193,600 --
Accounts payable, accrued liabilities and other liabilities (316,021) 51,529
Unearned purchase discount (73,901) (3,466)
Deposit related party (168,750) --
Other assets -- (2,001)
Advances on contracts in progress (378,438) (58,691)
------------ ------------
Net cash used in operating activities (2,925,308) (324,438)
------------ ------------
Cash flows provided by investing activities:
--------------------------------------------
Proceeds from sale of license 3,000,000 4,989,150
Additions to property and equipment (197,014) (411,442)
Acquisition, net of cash acquired -- (954,351)
Increase in intangible and other assets (305,045) (93,402)
------------ ------------
Net cash provided by investing activities 2,497,941 3,529,955
------------ ------------
Cash flows from financing activities:
-------------------------------------
Principal payments on capital lease obligation (184,033) (29,022)
Principal payments on capital lease obligation - related party (171,480) (33,028)
Exercise of stock options 132,443 12,215
------------ ------------
Net cash used in financing activities (223,070) (49,835)
------------ ------------
Net increase (decrease) in cash and cash equivalents (650,437) 3,155,682
Cash and cash equivalents, beginning of period 5,999,091 7,798,716
------------ ------------
Cash and cash equivalents, end of period $ 5,348,654 $ 10,954,398
============ ============
Supplemental disclosures of cash flow information:
--------------------------------------------------
Acquisition of Bandwidth Semiconductor:
Assets acquired $ -- $ 3,998,595
Liabilities assumed (including related party obligation
of $1,247,241) -- (3,044,244)
------------ ------------
Cash paid $ -- $ 954,351
============ ============
Non cash financing activities:
Capital lease obligation for building - related party $ -- $ 3,390,397
============ ============
Cash paid during the period for:
Interest $ 31,077 $ 18,031
============ ============
Interest - related party $ 109,771 $ 22,972
============ ============
Income taxes $ -- $ 435,000
============ ============
See accompanying notes to condensed consolidated financial statements.
3
SPIRE CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
JUNE 30, 2004
1. DESCRIPTION OF THE BUSINESS
The Company develops, manufactures and markets highly-engineered products
and services in four principal business areas: biomedical, solar equipment,
solar systems and optoelectronics, generally bringing to bear expertise in
materials technologies, surface science and thin films across all four business
areas.
In the biomedical area, the Company provides value-added surface
treatments to manufacturers of orthopedic and other medical devices that enhance
the durability, antimicrobial characteristics or other material characteristics
of their products; develops and markets hemodialysis catheters and related
devices for the treatment of chronic kidney disease; and performs sponsored
research programs into practical applications of advanced biomedical and
biophotonic technologies.
In the solar equipment area, the Company develops, custom manufactures
and markets specialized equipment for the production of terrestrial photovoltaic
modules from solar cells. The Company's equipment has been installed in more
than 150 factories in 42 countries.
In the solar systems area, the Company provides both stand alone
emergency power backup and electric power grid-connected distributed power
generation systems employing photovoltaic technology.
In the optoelectronics area, the Company provides compound semiconductor
foundry and fabrication services on a merchant basis to customers involved in
biomedical/biophotonic instruments, telecommunications and defense applications.
Services include compound semiconductor wafer growth, other thin film processes
and related device processing and fabrication services. The Company also
provides materials testing services and performs services in support of
sponsored research into practical applications of optoelectronic technologies.
2. INTERIM FINANCIAL STATEMENTS
In the opinion of management, the accompanying unaudited condensed
consolidated financial statements contain all adjustments necessary to fairly
present the Company's financial position as of June 30, 2004 and the results of
operations and cash flows for the three and six months ended June 30, 2004 and
2003. The results of operations for the three and six months ended June 30, 2004
are not necessarily indicative of the results to be expected for the fiscal year
ending December 31, 2004. The unaudited condensed consolidated statements of
cash flows for the six months ended June 30, 2003 has been updated to reflect
the final allocation of purchase price related to the Bandwidth Semiconductor,
LLC ("Bandwidth") acquisition.
The accounting policies followed by the Company are set forth in Note 2
to the Company's consolidated financial statements in its annual report on Form
10-KSB for the year ended December 31, 2003.
3. NEW ACCOUNTING STANDARD
In January 2003, the FASB issued FASB Interpretation No. 46,
"Consolidation of Variable Interest Entities" ("FIN 46") which requires the
consolidation of variable interest entities by the primary beneficiary of the
entity if the equity investors in the entity do not have the characteristics of
a controlling financial interest or do not have sufficient equity at risk for
the entity to finance its activities without additional subordinated financial
support from other parties. In December 2003, the FASB issued FASB
Interpretation No. 46R, "Consolidation of Variable Interest Entities" ("FIN
46R"). FIN 46R superseded FIN 46 and defers the effective date for small
business filers until the first reporting period that ends after December 15,
2004 (fourth quarter of 2004). The Company adopted of FIN 46R on January 1, 2004
and adoption did not have a material impact on the Company's financial position
or results of operations.
4
SPIRE CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(UNAUDITED)
JUNE 30, 2004
4. ACCOUNTS RECEIVABLE/ADVANCES ON CONTRACTS IN PROGRESS
Net accounts receivable, trade consists of the following:
JUNE 30,
2004
----------
Amounts billed $3,627,492
Retainage 37,505
Unbilled costs 682,880
----------
4,347,877
Less: Allowance for sales
returns and doubtful accounts (203,509)
----------
Net accounts receivable $4,144,368
==========
Unbilled costs on contracts in progress represent revenues recognized on
contracts for which billings have not been presented to customers as of the
balance sheet date. These amounts are billed and generally collected within one
year.
Retainage represents revenues on certain United States government
sponsored research and development contracts. These amounts, which usually
represent 15% of the Company's research fee on each applicable contract, are not
collectible until a final cost review has been performed by government auditors.
Included in retainage are amounts expected to be collected after one year, which
totaled $38,000 at June 30, 2004. All other accounts receivable are expected to
be collected within one year.
All contracts with United States government agencies have been audited by
the government through December 2000. The Company has not incurred significant
losses as a result of government audits.
The Company maintains allowances for doubtful accounts for estimated
losses resulting from the inability of its customers to pay amounts due. Bad
debts are written off against the allowance when identified. In addition, the
Company maintains an allowance for potential future product returns and rebates
related to current period revenues. The Company analyzes the rate of historical
returns when evaluating the adequacy of the allowance for sales returns and
allowances. Returns and rebates are charged against the allowance when incurred.
Advances on contracts in progress represent contracts for which billings
have been presented to the customer but revenue has not been recognized.
Advances on contracts in progress totaled $801,000 at June 30, 2004.
5. INVENTORIES
Inventories consist of the following:
JUNE 30,
2004
----------
Raw materials $1,130,518
Work in process 734,015
Finished goods 124,029
----------
$1,988,562
==========
5
SPIRE CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(UNAUDITED)
JUNE 30, 2004
6. EARNINGS (LOSS) PER SHARE
The following table provides a reconciliation of the denominators of the
Company's reported basic and diluted earnings (loss) per share computations for
the periods ended:
THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30,
------------------------- -------------------------
2004 2003 2004 2003
---------- ---------- ---------- ----------
Weighted average number of common and
common equivalent shares outstanding - basic 6,789,206 6,761,660 6,777,368 6,759,127
Add: net additional common shares upon
assumed exercise of common stock options 273,417 42,743 -- 29,019
---------- ---------- ---------- ----------
Adjusted weighted average common and
common equivalents shares outstanding - diluted 7,062,623 6,804,403 6,777,368 6,788,146
========== ========== ========== ==========
For the six months ended June 30, 2004, 263,234 shares of common stock
issuable relative to stock options were excluded from the calculation of
dilutive shares since the inclusion of such shares would be anti-dilutive due to
the Company's net loss position in the period. In addition, for the three and
six months ended June 30, 2004, 80,069 and 67,815 shares, respectively, and for
the three and six months ended June 30, 2003, 452,978 and 580,190 shares,
respectively, of common stock issuable relative to stock options had exercise
prices per share that exceeded the average market price of the Company's common
stock and were excluded from the calculation of diluted shares since their
inclusion would be anti-dilutive.
7. OPERATING SEGMENTS AND RELATED INFORMATION
The following table presents certain operating division information in
accordance with the provisions of SFAS No. 131, "Disclosure about Segments of an
Enterprise and Related Information", which was adopted in 1998.
The results for Bandwidth Semiconductor have been combined with the
Company's Biophotonics Lifesciences segment which has been renamed the
Optoelectronics segment. The acquisition of Bandwidth took place on May 23,
2003.
SOLAR SOLAR TOTAL
EQUIPMENT SYSTEMS BIOMEDICAL OPTOELECTRONICS COMPANY
------------ ------------ ------------ ------------ ------------
For the three months ended June 30, 2004
----------------------------------------
Net sales and revenues $ 813,024 $ 510,550 $ 2,323,307 $ 610,984 $ 4,257,865
Earnings (loss) from operations (506,278) (152,209) 2,592,041 (584,315) 1,349,239
For the three months ended June 30, 2003
----------------------------------------
Net sales and revenues $ 951,224 $ 810,197 $ 1,670,737 $ 322,763 $ 3,754,921
Earnings (loss) from operations (488,333) (145,620) 4,724,377 (132,632) 3,957,792
For the six months ended June 30, 2004
--------------------------------------
Net sales and revenues $ 1,974,691 $ 1,787,871 $ 4,180,699 $ 1,344,870 $ 9,288,131
Earnings (loss) from operations (669,203) (62,059) 1,768,006 (996,171) 40,573
For the six months ended June 30, 2003
--------------------------------------
Net sales and revenues $ 2,194,585 $ 810,197 $ 3,306,322 $ 402,910 $ 6,714,014
Earnings (loss) from operations (555,646) (546,062) 4,420,876 (142,514) 3,176,654
6
SPIRE CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(UNAUDITED)
JUNE 30, 2004
The following table shows net sales and revenues by geographic area
(based on customer location):
THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30,
------------------------------------------- ------------------------------------------
2004 % 2003 % 2004 % 2003 %
---------- ------- ---------- ------- ---------- ------- ---------- -------
Foreign $ 910,000 21% $ 859,000 23% $1,151,000 12% $2,111,000 31%
United States 3,348,000 79% 2,896,000 77% 8,137,000 88% 4,603,000 69%
---------- ------- ---------- ------- ---------- ------- ---------- -------
$4,258,000 100% $3,755,000 100% $9,288,000 100% $6,714,000 100%
========== ======= ========== ======= ========== ======= ========== =======
Revenues from contracts with United States government agencies for the
three months ended June 30, 2004 and 2003 were $819,000 and $615,000, or 19% and
16% of consolidated net sales and revenues, respectively.
Revenues from contracts with United States government agencies for the
six months ended June 30, 2004 and 2003 were $1,465,000 and $1,313,000, or 16%
and 20% of consolidated net sales and revenues, respectively.
One customer accounted for approximately 16% and three customers
accounted for approximately 36% of the Company's gross sales during the three
months ended June 30, 2004 and 2003, respectively. Two customers accounted for
approximately 27% and two customers accounted for approximately 36% of the
Company's gross sales during the six months ended June 30, 2004 and 2003,
respectively. One customer represented approximately 18% of trade account
receivables at June 30, 2004.
8. OTHER INTANGIBLE ASSETS
Patents amounted to $491,423 net of accumulated amortization of $543,042
at June 30, 2004. Licenses amounted to $193,333 net of accumulated amortization
of $31,667 at June 30, 2004. Patent cost is primarily composed of cost
associated with securing and registering patents that the Company has been
awarded or that have been submitted to, and the Company believes will be
approved by the government. These costs are capitalized and amortized over their
useful lives or terms, ordinarily five years, using the straight-line method.
There are no expected residual values related to these patents. For disclosure
purposes, the table below includes future amortization expense for patents owned
by the Company as well as $382,217 of estimated amortization expense related to
patents that remain pending. Estimated amortization expense for the periods
ending December 31, is as follows:
YEAR AMORTIZATION EXPENSE
---- --------------------
2004 $ 78,420
2005 156,160
2006 151,328
2007 148,153
2008 112,474
2009 38,221
--------------------
$684,756
--------------------
9. NOTES PAYABLE AND CREDIT ARRANGEMENTS
On June 23, 2003, the Company entered into a $2,000,000 Loan Agreement
(the "Agreement") with Citizens Bank of Massachusetts. The Agreement provides
Standby Letter of Credit Guarantees for foreign customers and is 100% secured
with cash. The Agreement had an original expiration date of June 30, 2004 and
was amended in June 2004 to extend the expiration date to June 28, 2005. The
amendment also suspended the Agreement's revolving line of credit conversion
feature for one year. At June 30, 2004, the Company had $671,000 of restricted
cash associated with outstanding letters of credit. Standby Letters of Credit
under this Agreement bear interest at 1%. A commitment fee of .25% is charged on
the unused portion of the borrowing base. The Agreement contains covenants
including certain financial reporting requirements. At June 30, 2004, the
Company was in compliance with its financial reporting requirements and cash
balance covenants. Letters of Credit issued with an expiration beyond June 28,
2005 are required to be 100% secured by cash.
7
SPIRE CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(UNAUDITED)
JUNE 30, 2004
10. STOCK-BASED COMPENSATION
The Company has adopted the disclosure provisions of Statement of
Financial Accounting Standards No. 148, "Accounting for Stock-Based Compensation
- Transition and Disclosure" ("SFAS 148") which is an amendment of SFAS No. 123
"Accounting for Stock-Based Compensation" ("SFAS 123"), and continues to apply
Accounting Principles Board Opinion No. 25 and related interpretations in
accounting for its stock plans. If the Company had elected to recognize
compensation cost for all of the plans based upon the fair value at the grant
dates for awards under those plans, consistent with the method prescribed by
SFAS 123, net earnings (loss) and earnings (loss) per share would have been
changed to the pro forma amounts indicated below.
THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30,
----------------------------- ------------------------------
2004 2003 2004 2003
------------ ------------ ------------ ------------
Net earnings (loss), as reported $ 1,278,710 $ 3,261,280 $ (99,345) $ 2,487,751
Deduct: Total stock-based employee compensation
expense determined under fair value based method
for all awards, net of related tax effects (80,424) (84,629) (158,888) (170,044)
------------ ------------ ------------ ------------
Pro forma net earnings (loss) $ 1,198,286 $ 3,176,651 $ (258,233) $ 2,317,707
============ ============ ============ ============
Earnings (loss) per share:
Basic - as reported $ 0.19 $ 0.48 $ (0.01) $ 0.37
============ ============ ============ ============
Basic - pro forma $ 0.18 $ 0.47 $ (0.04) $ 0.34
============ ============ ============ ============
Diluted - as reported $ 0.18 $ 0.48 $ (0.01) $ 0.37
============ ============ ============ ============
Diluted - pro forma $ 0.17 $ 0.47 $ (0.04) $ 0.34
============ ============ ============ ============
The per-share weighted-average fair value of stock options granted during the
quarters ended June 30, 2004 and 2003 was $4.73 and $2.39, respectively, on the
date of grant using the Black-Scholes option-pricing model with the following
weighted-average assumptions:
EXPECTED RISK-FREE EXPECTED EXPECTED
YEAR DIVIDEND YIELD INTEREST RATE OPTION LIFE VOLATILITY FACTOR
---- -------------- ------------- ----------- -----------------
2004 -- 3.83% 5 years 78.2%
2003 -- 3.33% 5 years 81.7%
For the quarter ended June 30, 2004, 8,250 stock options were granted.
11. SALE OF A LICENSE
In October 2002, the Company sold an exclusive patent license for a
hemodialysis split-tip catheter to Bard Access Systems, Inc. ("Bard"), a wholly
owned subsidiary of C. R. Bard, Inc., in exchange for $5,000,000 upon the
execution of the agreement, with another $5,000,000 due upon the earlier to
occur of: (a) the date of the first commercial sale of a licensed product by
Bard; or (b) no more than 18 months after signing. The agreement further
provided for two additional contingent cash payments of $3,000,000 each upon the
completion of certain milestones by Bard in 2004 and 2005. Bard has the right to
cancel the agreement at any time subsequent to the second payment. There can be
no assurances that these milestones will be attained and attainment is beyond
the control of the Company. During the year ended December 31, 2002, the Company
recorded the initial payment under the agreement, resulting in a gain of
$4,464,929, net of direct costs. Due to the potential length of time between the
first and second payments and the cancellation provisions within the agreement,
the Company did not record the potential remaining payments at that time. During
June 2003, in accordance with the agreement, the Company received notification
from Bard of the first commercial sale, collected the $5,000,000
8
SPIRE CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(UNAUDITED)
JUNE 30, 2004
payment due and recorded a gain of $4,989,150, net of direct costs. During June
2004, the Company received the first contingent milestone payment and recorded a
gain of $3,000,000. There were no direct costs associated with this payment.
These gains have been recorded in the accompanying unaudited condensed
consolidated statements of operations for the three and six months ended June
30, 2004 and 2003, respectively. The Company believes that the sale of the
license does not reflect the day-to-day operations of the Company. Therefore,
the net proceeds received has been classified under investing activities in the
unaudited condensed consolidated statements of cash flows for the six months
ended June 30, 2004 and June 30, 2003, respectively.
In conjunction with the sale, the Company received a sublicense, which
permits the Company to continue to manufacture and market hemodialysis catheters
for the treatment of chronic kidney disease. In addition, the Company granted
Bard a right of first refusal should the Company seek to sell the catheter
business.
12. COMMITMENTS
Letters of Credit
-----------------
During the second quarter of 2004, the Company entered into a Purchase
and Sale Agreement (the "Agreement") to supply certain solar systems units and
equipment to a third party. Performance under the Agreement is subject to
several precedent conditions including the issuance of a Standby Letter of
Credit by the Company in favor of the third party and the advance funding of the
total purchase price by the third party to Spire. On July 1, 2004, Spire issued
a $5,860,249 Standby Letter of Credit, as amended, in accordance with the terms
of this Agreement. The Standby Letter of Credit is subject to the terms of the
Company's Loan Agreement as discussed in Note 9 and is only available for
drawing to the extent that payments are received by the Company from the third
party. As of August 12, 2004, no advance payments have been received. The
Standby Letter of Credit automatically terminates if payment is not received by
August 31, 2004.
Related Party Capital Lease
---------------------------
In conjunction with the acquisition of Bandwidth by the Company,
SPI-Trust, a Trust of which Roger G. Little, Chairman of the Board, Chief
Executive Officer and President of the Company, is sole trustee and principal
beneficiary, purchased from Stratos (Bandwidth's owner) the building that
Bandwidth occupies in Hudson, New Hampshire for $3.7 million. Subsequently, the
Company entered into a lease for the building (90,000 square feet) with
SPI-Trust whereby the Company will pay $4.1 million to SPI-Trust over an initial
five year term expiring in 2008 with a Company option to extend for five years.
In addition to the rent payments, the lease obligates the Company to keep on
deposit with SPI-Trust the equivalent of three months rent ($168,750 as of June
30, 2004). The lease agreement does not provide for a transfer of ownership at
any point. Interest costs were assumed at 7%. For the six months ended June 30,
2004, interest expense was approximately $110,000. This lease has been
classified as a related party capital lease and a summary of payments (including
interest) follows:
RATE PER MONTHLY SECURITY
YEAR SQUARE FOOT ANNUAL RENT RENT DEPOSIT
--------------------------- ----------- ----------- ------- --------
June 1, 2003 - May 31, 2004 $ 6.00 $ 540,000 $45,000 $135,000
June 1, 2004 - May 31, 2005 7.50 675,000 56,250 168,750
June 1, 2005 - May 31, 2006 8.50 765,000 63,750 191,250
June 1, 2006 - May 31, 2007 10.50 945,000 78,750 236,250
June 1, 2007 - May 31, 2008 13.50 1,215,000 101,250 303,750
-----------
$ 4,140,000
===========
At June 30, 2004, $485,461 and $2,545,695 are reflected as the current
and long-term portions of capital lease obligation - related party,
respectively, in the June 30, 2004 unaudited condensed consolidated balance
sheet.
9
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
THIS MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS SECTION AND OTHER PARTS OF THIS REPORT CONTAIN
FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES. THE COMPANY'S
ACTUAL RESULTS AND THE TIMING OF CERTAIN EVENTS MAY DIFFER SIGNIFICANTLY FROM
THE RESULTS AND TIMING DISCUSSED IN THE FORWARD-LOOKING STATEMENTS. FACTORS THAT
COULD CAUSE OR CONTRIBUTE TO SUCH DIFFERENCES INCLUDE, BUT ARE NOT LIMITED TO,
THOSE DISCUSSED OR REFERRED TO IN THIS REPORT AND IN ITEM 6 OF THE ANNUAL REPORT
ON FORM 10-KSB FOR THE YEAR ENDED DECEMBER 31, 2003. MANAGEMENT'S DISCUSSION AND
ANALYSIS INCLUDES THE FOLLOWING SECTIONS:
o OVERVIEW;
o RESULTS OF OPERATIONS;
o THREE AND SIX MONTHS ENDED JUNE 30, 2004 COMPARED TO THREE AND SIX
MONTHS ENDED JUNE 30, 2003;
o LIQUIDITY AND CAPITAL RESOURCES;
o RECENT ACCOUNTING PRONOUNCEMENTS;
o IMPACT OF INFLATION AND CHANGING PRICES;
o FOREIGN CURRENCY FLUCTUATION;
o RELATED PARTY TRANSACTIONS;
o CRITICAL ACCOUNTING POLICIES; AND
o CONTRACTUAL OBLIGATIONS, COMMERCIAL COMMITMENTS AND OFF-BALANCE
SHEET ARRANGEMENTS.
Overview
--------
The Company develops, manufactures and markets highly-engineered products
and services in four principal business areas: biomedical, solar equipment,
solar systems and optoelectronics, generally bringing to bear expertise in
materials technologies, surface science and thin films across all four business
areas.
In the biomedical area, the Company provides value-added surface
treatments to manufacturers of orthopedic and other medical devices that enhance
the durability, antimicrobial characteristics or other material characteristics
of their products; develops and markets hemodialysis catheters and related
devices for the treatment of chronic kidney disease; and performs sponsored
research programs into practical applications of advanced biomedical and
biophotonic technologies.
In the solar equipment area, the Company develops, custom manufactures
and markets specialized equipment for the production of terrestrial photovoltaic
modules from solar cells. The Company's equipment has been installed in more
than 150 factories in 42 countries.
In the solar systems area, the Company provides both stand alone
emergency power backup and electric power grid-connected distributed power
generation systems employing photovoltaic technology.
In the optoelectronics area, the Company provides compound semiconductor
foundry and fabrication services on a merchant basis to customers involved in
biomedical/biophotonic instruments, telecommunications and defense applications.
Services include compound semiconductor wafer growth, other thin film processes
and related device processing and fabrication services. The Company also
provides materials testing services and performs services in support of
sponsored research into practical applications of optoelectronic technologies.
Results of Operations
---------------------
The following table sets forth certain items as a percentage of net sales
and revenues for the periods presented:
THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30,
--------------------- ---------------------
2004 2003 2004 2003
------ ------ ------ ------
Net sales and revenues 100% 100% 100% 100%
Cost of sales and revenues 82 79 80 78
------ ------ ------ ------
Gross profit 18 21 20 22
Selling, general and administrative expenses (48) (40) (44) (43)
Internal research and development (9) (8) (8) (6)
Gain on sale of license 71 133 32 74
------ ------ ------ ------
Earnings from operations 32 106 -- 47
Interest expense, net (2) (1) (1) --
------ ------ ------ ------
Earnings (loss) before income taxes 30 105 (1) 47
Income tax expense -- 18 -- 10
------ ------ ------ ------
Net earnings (loss) 30% 87% (1%) 37%
====== ====== ====== ======
10
The Company's total net sales and revenues for the six months ended June
30, 2004 ("2004") increased 38% compared to the six months ended June 30, 2003
("2003"). The increase was attributable to an increase in solar systems in 2004
(15%), the acquisition of Bandwidth Semiconductor, LLC ("Bandwidth") in May 2003
(16%), and to a lesser extent, increases in biomedical processing services and
devices (11%) and government funded research and development activities (4%).
These increases were partially offset by a decrease in solar equipment sales
(8%).
Sales in the Company's solar business unit increased 25% during 2004 as
compared to 2003 primarily due to a 121% increase in solar systems sales
resulting from the temporary permitting challenges in the metro Chicago area we
experienced in 2003 that we did not encounter in 2004. The increase can also be
attributed to a 220% increase in revenue from government-funded research and
development activities associated with our cost sharing agreement with the
Department of Energy National Renewable Energy Laboratory ("NREL"). These
increases were partially offset by a 27% decrease in equipment sales in 2004 of
the Company's solar energy manufacturing equipment as compared to 2003. Sales in
2004 consisted primarily of two assemblers and two simulators as compared to the
shipment of a 5 megawatt SPI-LINETM turnkey photovoltaic module production line
to Huangshan Ho Tin Solar Technology Development Ltd. located in China in 2003.
Revenues of the Company's biomedical business unit increased 22% during
2004 as compared to 2003 as a result of a 23% increase in revenue from our
IONGUARD(R) implant process services and a 65% increase in revenue from our line
of hemodialysis catheters and, to a lesser extent, a 3% increase in revenue from
our government-funded research and development activities.
Sales in the Company's optoelectronics business unit increased 380%
during 2004 as compared to 2003, due to the May 23, 2003 acquisition of
Bandwidth Semiconductor, LLC ("Bandwidth").
Operating results will depend upon product mix, as well as the timing of
shipments of higher priced products from the Company's solar equipment line and
delivery of solar systems. Export sales were 12% of net sales and revenues in
2004 and are expected to continue to constitute a significant portion of the
Company's net sales and revenues.
Three and Six Months Ended June 30, 2004 Compared to Three and Six Months Ended
-------------------------------------------------------------------------------
June 30, 2003
-------------
NET SALES AND REVENUES
The following table categorizes the Company's net sales and revenues for
the periods presented:
THREE MONTHS ENDED JUNE 30, INCREASE/(DECREASE)
--------------------------- ---------------------------
2004 2003 $ %
------------ ------------ ------------ ------------
Contract research and service revenues $ 2,749,000 $ 1,927,000 $ 822,000 43%
Sales of goods 1,509,000 1,828,000 (319,000) (17%)
------------ ------------ ------------
Net sales and revenues $ 4,258,000 $ 3,755,000 $ 503,000 13%
============ ============ ============
The 43% increase in contract research and service revenues for the three
months ended June 30, 2004 as compared to the three months ended June 30, 2003
is primarily attributable to the acquisition of Bandwidth (17%) on May 23, 2003,
an increase in research and development activities (17%), and to a lesser
extent, increases in biomedical processing services (7%) and royalty fees (2%).
Revenues from our research and development activities increased 54% in 2004 as
compared to 2003 primarily due to an increase in the value and number of
contracts associated with funded research and development and an increase in
revenue from activities associated with our cost sharing agreement with NREL.
Revenue from our biomedical processing services increased 13% in 2004 compared
to 2003 as a result of continued strong demand for our IONGUARD implant
services.
The 17% decrease in sales of goods for the three months ended June 30,
2004 as compared to the three months ended June 30, 2003 was primarily due to a
decrease in solar systems revenues (16%) and a decrease in solar equipment sales
(16%) both offset by an increase in biomedical product sales (15%). Solar
systems revenues decreased 37% in 2004 as compared to 2003 due to the timing of
project installations in 2004 as compared to 2003. Solar equipment sales
decreased 36% in 2004 as compared to 2003 primarily due to the timing and
delivery of customer orders. Biomedical product sales increased 134% in 2004 as
compared to 2003 as a result of increased demand for our line of hemodialysis
catheters and initial sales of our Decathlon product line which was introduced
in December 2003.
11
The following table categorizes the Company's net sales and revenues for
the periods presented:
SIX MONTHS ENDED JUNE 30, INCREASE/(DECREASE)
--------------------------- ---------------------------
2004 2003 $ %
------------ ------------ ------------ ------------
Contract research and service revenues $ 5,331,000 $ 3,519,000 $ 1,812,000 51%
Sales of goods 3,957,000 3,195,000 762,000 24%
------------ ------------ ------------
Net sales and revenues $ 9,288,000 $ 6,714,000 $ 2,574,000 38%
============ ============ ============
The 51% increase in contract research and service revenues for the six
months ended June 30, 2004 is primarily attributable to the acquisition of
Bandwidth (30%) on May 23, 2003, and to a lesser extent, an increase in
biomedical processing services (12%) and an increase in government-funded
research and development activities associated with our cost sharing agreement
with NREL (9%). Revenue from our biomedical processing services increased 23% in
2004 compared to 2003 as a result of continued strong demand for our IONGUARD
implant services.
The 24% increase in sales of goods for the six months ended June 30, 2004
was primarily due to an increase in solar systems revenues (31%) and, to a
lesser extent, an increase in biomedical product sales (9%), both offset by a
decrease in solar equipment sales (16%). The increase in solar system revenues
was primarily due to a 122% increase in solar systems revenue in 2004 as
compared to 2003 resulting from the temporary permitting challenges in the metro
Chicago area we experienced in 2003 that were not encountered in 2004.
Biomedical product sales increased 65% in 2004 as compared to 2003 as a result
of increased demand for our line of hemodialysis catheters and initial sales of
our Decathlon product line which was introduced in December 2003. Solar
equipment sales decreased 27% in 2004 as compared to 2003 primarily attributable
to the sale of two assemblers and two simulators in 2004 as compared to the
shipment of a 5 megawatt SPI-LINE turnkey production line in 2003.
COST OF SALES AND REVENUES
The following table categorizes the Company's cost of sales and revenues
for the periods presented, stated in dollars and as a percentage of related
sales and revenues:
THREE MONTHS ENDED JUNE 30, INCREASE/(DECREASE)
------------------------------------------ -------------------
2004 % 2003 % $ %
---------- ----- ---------- ----- ---------- -----
Cost of contract research and services $2,113,000 77% $1,256,000 65% $ 857,000 68%
Cost of goods sold 1,388,000 92% 1,722,000 94% (334,000) (19%)
---------- ---------- ----------
Net cost of sales and revenues $3,501,000 82% $2,978,000 79% $ 523,000 18%
========== ========== ==========
The $857,000 (68%) increase in cost of contract research and service
revenues in 2004 is primarily due to increased factory overhead and direct costs
of $599,000 (48%) associated with the Company's semiconductor foundry and a
$254,000 (20%) increase in biomedical processing services costs associated with
its 13% increase in revenues. The decline in profit margins associated with the
biomedical processing services is primarily attributable to product mix. The
increase in cost of contract research and services as a percentage of revenues
is the direct result of the Bandwidth acquisition, which recorded a -44% gross
margin in 2004.
The decrease in cost of goods sold as a percentage of revenue is the
result of improved contribution margins at our Chicago facility and increased
contribution from our hemodialysis catheter product line. The decrease was
offset in part by reduced absorption of fixed costs with our equipment product
line as a result of reduced revenue (-36%) for the same period last year.
COST OF SALES AND REVENUES
SIX MONTHS ENDED JUNE 30, INCREASE/(DECREASE)
------------------------------------------ -------------------
2004 % 2003 % $ %
---------- ----- ---------- ----- ---------- -----
Cost of contract research and services $4,119,000 77% $2,255,000 64% $1,864,000 83%
Cost of goods sold 3,309,000 84% 3,010,000 94% 299,000 10%
---------- ---------- ----------
Net cost of sales and revenues $7,428,000 80% $5,265,000 78% $2,163,000 41%
========== ========== ==========
12
The $1,864,000 (83%) increase in cost of contract research and service
revenues in 2004 is primarily due to increased factory overhead and direct costs
of $1,451,000 (64%) associated with the Company's semiconductor foundry and a
$471,000 (21%) increase in biomedical processing services costs associated with
its 23% increase in revenues. The increase was offset in part by a decrease in
cost of sales associated with our research and development activities (2%). The
increase in cost of contract research and services as a percentage of revenues
is the direct result of the Bandwidth acquisition, which recorded a -28% gross
margin in 2004.
The decrease in cost of goods sold as a percentage of revenue is the
result of improved contribution margins at the Chicago facility and increased
contribution from our hemodialysis catheter product line. The decrease was
offset in part by reduced absorption of fixed costs with our equipment product
line as a result of reduced revenue (-27%) for the same period last year.
INTERNAL RESEARCH AND DEVELOPMENT
Internal research and development for the three months ended June 30,
2004 increased $94,000 or 33% to $377,000, compared to $283,000 for the three
months ended June 30, 2003. The increase was primarily a result of the Company's
continued investment in its semiconductor foundry and the "next generation"
solar energy module manufacturing equipment under a cost-sharing contract with
NREL. As a percentage of sales and revenues, internal research and development
increased 1% primarily due to the continued investments discussed above
partially offset by the increase in sales and revenue.
Internal research and development for the six months ended June 30, 2004
increased $352,000 or 93% to $731,000, compared to $379,000 for the six months
ended June 30, 2003. The increase was primarily a result of the Company's
continued investment in its semiconductor foundry and the "next generation"
solar energy module manufacturing equipment under a cost-sharing contract with
NREL. As a percentage of sales and revenues, internal research and development
increased 2% primarily due to the continued investments discussed above
partially offset by the increase in sales and revenue.
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES
Selling, general and administrative expenses for the three months ended
June 30, 2004 increased $505,000 to $2,030,000, or 48% of sales and revenues,
compared to $1,525,000 or 40% of sales and revenues for the three months ended
June 30, 2003. The increase was due primarily to increased cost associated with
sales and marketing efforts of the Company's biomedical products and solar
business unit and the addition of Bandwidth. The increase in selling, general
and administrative expenses as a percentage of sales and revenues was primarily
due to the dollar increases described above partially offset by the increase in
sales and revenue.
Selling, general and administrative expenses for the six months ended
June 30, 2004 increased $1,207,000 to $4,089,000, or 44% of sales and revenues,
compared to $2,882,000 or 43% of sales and revenues for the six months ended
June 30, 2003. The increase was due primarily to increased costs associated with
sales and marketing efforts of the Company's biomedical products and solar
business units, the addition of Bandwidth and increased costs associated with
legal and auditing expenses in connection with increased compliance
requirements. The increase in selling, general and administrative expenses as a
percentage of sales and revenues was primarily due to the dollar increases
described above partially offset by the increase in sales and revenue.
INTEREST
The Company earned $14,000 and $17,000 of interest income for the
quarters ended June 30, 2004 and 2003, respectively. The Company incurred
interest expense of $84,000 and $39,000 for the quarters ended June 30, 2004 and
2003, respectively. The interest expense is primarily associated with interest
incurred on capital leases associated with the semiconductor foundry.
The Company earned $34,000 and $40,000 of interest income for the six
months ended June 30, 2004 and 2003, respectively. The Company incurred interest
expense of $174,000 and $54,000 for the six months ended June 30, 2004 and 2003,
respectively. The interest expense is primarily associated with interest
incurred on capital leases associated with the semiconductor foundry.
13
INCOME TAXES
The Company incurred zero income tax expense for the quarter and the six
months ended June 30, 2004, compared to income tax expense of $675,000 for the
quarter and the six months ended June 30, 2003. The effective tax rate was 17%
for the quarter ended June 30, 2003 and 21% for the six months ended June 30,
2003.
NET EARNING (LOSS)
The Company reported net earnings for the three months ended June 30,
2004 of $1,279,000, compared to net earnings of $3,261,000 in 2003. The earnings
for the quarter ended June 30, 2004 are attributable to the Company's income
associated with the $3,000,000 contingent milestone payment received relating to
the sale of a license for the Company's hemodialysis spilt-tip catheter. The
earnings for the quarter ended June 30, 2003 were attributable to the payment of
$5,000,000 relating to the hemodialysis license sale that resulted in a
$4,989,000 gain. While revenue increased in the quarter, the breakeven point of
the Company rose primarily due to the increased fixed costs associated with the
Company's semiconductor foundry.
The Company reported a net loss for the six months ended June 30, 2004 of
$99,000, compared to net earnings of $2,488,000 in 2003. The loss for the six
months ended June 30, 2004 is attributable to the Company's operations as
outlined above offset by to the Company's income associated with the $3,000,000
gain on the sale of license. The earnings for the six months ended June 30, 2003
were attributed to the payment of $5,000,000 relating to the hemodialysis
license sale resulting in a $4,989,000 gain. While revenue increased in the
quarter, the breakeven point of the Company rose primarily due to the increased
fixed costs associated with the Company's semiconductor foundry.
Liquidity and Capital Resources
-------------------------------
Cash and cash equivalents decreased $650,000 to $5,349,000 as of June 30,
2004 primarily due to $2,925,000 of cash used in operations and, to a lesser
extent, investments in patents and licenses and payments on capital leases.
These decreases were substantially offset by the $3,000,000 license payment.
The Company has historically funded its operating cash requirements using
operating cash flow and proceeds from the sale and licensing of technology. The
Company's liquidity position benefited as a result of cash receipts of
$5,000,000 in each of the years ended December 31, 2003 and 2002, and $3,000,000
in the quarter ended June 30, 2004 arising from the sale of a hemodialysis
patent license to Bard Access Systems. The license sale agreement provides for
the Company to receive one additional contingent cash payment of $3,000,000 upon
the completion of certain milestones by Bard Access Systems during 2005. There
can be no assurance that these milestones will be attained and attainment is
beyond the control of the Company.
On June 23, 2003, the Company entered into a $2,000,000 Loan Agreement
(the "Agreement") with Citizens Bank of Massachusetts. The Agreement provides
Standby Letter of Credit Guarantees for foreign customers and is 100% secured
with cash. The Agreement had an original expiration date of June 30, 2004 and
was amended in June 2004 to extend the expiration date to June 28, 2005. The
amendment also suspended the Agreement's revolving line of credit conversion
feature for one year. At June 30, 2004, the Company had $671,000 of restricted
cash associated with outstanding letters of credit. Standby Letters of Credit
under this Agreement bear interest at 1%. A commitment fee of .25% is charged on
the unused portion of the borrowing base. The Agreement contains covenants
including certain financial reporting requirements. At June 30, 2004, the
Company was in compliance with its financial reporting requirements and cash
balance covenants. Letters of Credit issued with an expiration beyond June 28,
2005 are required to be 100% secured by cash.
To date, there are no material commitments by the Company for capital
expenditures. At June 30, 2004, the Company's retained earnings were $2,371,000,
compared to retained earnings of $2,470,000 as of December 31, 2003. Working
capital as of June 30, 2004 decreased to $8,012,000, compared to $8,182,000 as
of December 31, 2003.
During the second quarter of 2004, the Company entered into a Purchase
and Sale Agreement (the "Agreement") to supply certain solar systems units and
equipment to a third party. Performance under the Agreement is subject to
several precedent conditions including the issuance of a Standby Letter of
Credit by the Company in favor of the third party and the advance funding of the
total purchase price by the third party to Spire. On July 1, 2004, Spire issued
a $5,860,249 Standby Letter of Credit, as amended, in accordance with the terms
of this Agreement. The Standby Letter of Credit is subject to the terms of the
Company's Loan Agreement as discussed in Note 9 and is only available for
drawing to the extent that payments are received by the Company from the third
party. As of August 12, 2004, no advance payments have been received. The
Standby Letter of Credit automatically terminates if payment is not received by
August 31, 2004.
14
The Company believes it has sufficient resources to finance its current
operations for the foreseeable future through working capital.
Recent Accounting Pronouncements
--------------------------------
In January 2003, the FASB issued FASB Interpretation No. 46,
"Consolidation of Variable Interest Entities" ("FIN 46") which requires the
consolidation of variable interest entities by the primary beneficiary of the
entity if the equity investors in the entity do not have the characteristics of
a controlling financial interest or do not have sufficient equity at risk for
the entity to finance its activities without additional subordinated financial
support from other parties. In December 2003, the FASB issued FASB
Interpretation No. 46R, "Consolidation of Variable Interest Entities" ("FIN
46R"). FIN 46R superseded FIN 46 and defers the effective date for small
business filers until the first reporting period that ends after December 15,
2004 (fourth quarter of 2004). The Company adopted of FIN 46R on January 1, 2004
and adoption did not have a material impact on the Company's financial position
or results of operations.
Impact of Inflation and Changing Prices
---------------------------------------
Historically, the Company's business has not been materially impacted by
inflation. Manufacturing equipment and solar systems are generally quoted,
manufactured and shipped within a cycle of approximately nine months, allowing
for orderly pricing adjustments to the cost of labor and purchased parts. The
Company has not experienced any negative effects from the impact of inflation on
long-term contracts. The Company's service business is not expected to be
seriously affected by inflation because its procurement-production cycle
typically ranges from two weeks to several months, and prices generally are not
fixed for more than one year. Research and development contracts usually include
cost escalation provisions.
Foreign Currency Fluctuation
----------------------------
The Company sells only in U.S. dollars, generally against an irrevocable
confirmed letter of credit through a major United States bank. Therefore the
Company is not directly affected by foreign exchange fluctuations on its current
orders. However, fluctuations in foreign exchange rates do have an effect on the
Company's customers' access to U.S. dollars and on the pricing competition on
certain pieces of equipment that the Company sells in selected markets.
Related Party Transactions
--------------------------
The Company subleases 74,000 square feet in a building leased by Mykrolis
Corporation, who in turn leases the building from a Trust of which Roger G.
Little, Chairman of the Board, Chief Executive Officer and President of the
Company, is sole trustee and principal beneficiary. The Company believes that
the terms of the third-party sublease are commercially reasonable. The 1985
sublease originally was for a period of ten years, was extended for a five-year
period expiring on November 30, 2000 and was further extended for a five-year
period expiring on November 30, 2005. The agreement provides for minimum rental
payments plus annual increases linked to the consumer price index. Rent expense
under this sublease for the six months ended June 30, 2004 was $533,000. In
connection with this sublease, the Company is invoiced and pays certain Trust
related expenses, including building maintenance and insurance. The Company
invoices the Trust on a monthly basis and the Trust reimburses the Company for
all such costs.
In conjunction with the acquisition of Bandwidth by the Company, the
Company released Bandwidth from the lease agreement that had existed between
Bandwidth and the Company. In November 2001, Bandwidth, under its previous
owner, abandoned the space being subleased from the Company in Bedford,
Massachusetts, to move to a new building and wafer fabrication lab in Hudson,
New Hampshire. At that time, there were 48 months left on the lease. Subsequent
to the move to Hudson, New Hampshire, Bandwidth was unable to sublease the
Bedford, Massachusetts space, and was paying the Company for the unused space.
In conjunction with the acquisition of Bandwidth in May 2003, the Company
released Bandwidth from the remaining lease payments. However, the Company
continues to be obligated to Mykrolis Corporation for the entire amount of the
remaining lease agreement. As a result, the present value of the remaining lease
obligation associated with the unused space was recorded as an assumed liability
of $1,247,241 in the purchase accounting. As of June 30, 2004, the remaining
lease obligation is $722,067, which is reflected as "accrued lease obligation -
related party" in the June 30, 2004 unaudited condensed consolidated balance
sheet. The amount due beyond one year has been reflected in long-term
liabilities. The difference between the actual rent payment and the discounted
rent payment will be accreted to the consolidated statements of operations as
interest expense. Interest of 4.75% has been assumed on this obligation. For the
six months ended June 30, 2004, interest expense was $20,532.
15
Also in conjunction with the acquisition of Bandwidth by the Company,
SPI-Trust, a Trust of which Roger G. Little, Chairman of the Board, Chief
Executive Officer and President of the Company, is sole trustee and principal
beneficiary, purchased from Stratos (Bandwidth's owner) the building that
Bandwidth occupies in Hudson, New Hampshire for $3.7 million. Subsequently, the
Company entered into a lease for the building (90,000 square feet) with
SPI-Trust whereby the Company will pay $4.1 million to SPI-Trust over an initial
five year term expiring in 2008 with a Company option to extend for five years.
In addition to the rent payments, the lease obligates the Company to keep on
deposit with SPI-Trust the equivalent of three months rent ($168,750 as of June
30, 2004). The lease agreement does not provide for a transfer of ownership at
any point. Interest costs were assumed at 7%. For the six months ended June 30,
2004, interest expense was approximately $110,000. This lease has been
classified as a related party capital lease and a summary of payments (including
interest) follows:
RATE PER MONTHLY SECURITY
YEAR SQUARE FOOT ANNUAL RENT RENT DEPOSIT
--------------------------- ----------- ----------- -------- --------
June 1, 2003 - May 31, 2004 $ 6.00 $ 540,000 $ 45,000 $135,000
June 1, 2004 - May 31, 2005 7.50 675,000 56,250 168,750
June 1, 2005 - May 31, 2006 8.50 765,000 63,750 191,250
June 1, 2006 - May 31, 2007 10.50 945,000 78,750 236,250
June 1, 2007 - May 31, 2008 13.50 1,215,000 101,250 303,750
-----------
$ 4,140,000
===========
At June 30, 2004, $485,461 and $2,545,695 are reflected as the current
and long-term portions of capital lease obligation - related party,
respectively, in the accompanying unaudited condensed consolidated balance sheet
Critical Accounting Policies
----------------------------
The preparation of financial statements in accordance with accounting
principles generally accepted in the United States requires us to make estimates
and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Among the significant estimates affecting our unaudited
condensed consolidated financial statements are those relating to revenue
recognition, impairment of long-lived assets, acquisition accounting, income
taxes, and warranties. We regularly evaluate our estimates and assumptions based
upon historical experience and various other factors that we believe to be
reasonable under the circumstances, the results of which form the basis for
making judgments about the carrying values of assets and liabilities that are
not readily apparent from other sources. To the extent actual results differ
from those estimates, our future results of operations may be affected. We
believe the following critical accounting policies affect our more significant
judgments and estimates used in the preparation of our unaudited condensed
consolidated financial statements. Refer to Footnote 2 of our notes to
consolidated financial statements in our annual report on Form 10-KSB for the
year ended December 31, 2003 for a description of our accounting policies for
income taxes and warranties.
REVENUE RECOGNITION
The Company derives its revenues from three primary sources: (1)
commercial products including, but not limited to, solar energy manufacturing
equipment, solar energy systems and hemodialysis catheters; (2) biomedical and
semiconductor processing services; and (3) United States government funded
research and development contracts.
We generally recognize product revenue upon shipment of products provided
there are no uncertainties regarding customer acceptance, persuasive evidence of
an arrangement exists, the sales price is fixed or determinable, and
collectibility is reasonably assured. These criteria are generally met at the
time of shipment when the risk of loss and title passes to the customer or
distributor, unless a consignment arrangement exists. Revenue from consignment
arrangements is recognized based on product usage indicating sales are complete.
Gross sales reflect reductions attributable to customer returns and various
customer incentive programs including pricing discounts and rebates. Product
returns are permitted in certain sales contracts and an allowance is recorded
for returns based on the Company's history of actual returns. Certain customer
incentive programs require management to estimate the cost of those programs.
The allowance for these programs is determined through an analysis of programs
offered, historical trends, expectations regarding customer and consumer
participation, sales and payment trends, and experience with payment patterns
associated with similar programs that had been previously offered. If sufficient
history to make reasonable and reliable estimates of returns or rebates does not
exist, revenue associated with such practices is deferred until the return
period lapses or a reasonable estimate can be made. This deferred revenue will
be recognized as revenue when the distributor reports to us that it has either
shipped or disposed of the units (indicating that the possibility of return is
remote.)
16
The Company's OEM capital equipment solar energy business builds complex
customized machines to order for specific customers. Substantially all of these
orders are sold on a FOB Bedford, Massachusetts (or EXW Factory) basis. It is
the Company's policy to recognize revenues for this equipment as the product is
shipped to the customer, as customer acceptance is obtained prior to shipment
and the equipment is expected to operate the same in the customer's environment
as it does in the Company's environment. When an arrangement with the customer
includes future obligations or customer acceptance, revenue is recognized when
those obligations are met or customer acceptance has been achieved. The
Company's solar energy systems business installs solar energy systems on
customer-owned properties on a contractual basis. Generally, revenue is
recognized once the systems have been installed and the title is passed to the
customer. For arrangements with multiple elements, the Company allocates fair
value to each element in the contract and revenue is recognized upon delivery of
the element.
The Company's biomedical subsidiary and semiconductor foundry and
fabrication unit perform specialty material processing services for various
manufacturers on a contractual basis. The Company recognizes revenue as the
processed products are shipped to the customer.
The Company recognizes revenues and estimated profits on long-term
government contracts on a percentage-of-completion method of accounting using a
cost-to-cost methodology. Profit estimates are revised periodically based upon
changes and facts, and any losses on contracts are recognized immediately. Some
of the contracts include provisions to withhold a portion of the contract value
as retainage until such time as the United States government performs an audit
of the cost incurred under the contract. The Company's policy is to take into
revenue the full value of the contract, including any retainage, as it performs
against the contract since the Company has not experienced any substantial
losses as a result of audits performed by the United States government.
IMPAIRMENT OF LONG-LIVED ASSETS
Long-lived assets, including fixed assets and intangible assets, are
continually monitored and are evaluated at least annually for impairment. The
determination of recoverability is based on an estimate of undiscounted cash
flows expected to result from the use of an asset and its eventual disposition.
The estimate of cash flows is based upon, among other things, certain
assumptions about expected future operating performance. Our estimates of
undiscounted cash flows may differ from actual cash flows due to, among other
things, technological changes, economic conditions, changes to our business
model or changes in our operating performance. If the sum of the undiscounted
cash flows (excluding interest) is less than the carrying value, we recognize an
impairment loss, measured as the amount by which the carrying value exceeds the
fair value of the asset.
ACQUISITION ACCOUNTING
Through its acquisition, the Company has accumulated assets, the
valuation of which involves estimates based on fair value assumptions. Estimated
lives assigned to the assets acquired in a business purchase also involve the
use of estimates. These matters that are subject to judgments and estimates are
inherently uncertain, and different amounts could be reported using different
methodologies. Management uses its best estimate in determining the appropriate
values and estimated lives to reflect in the consolidated financial statements,
using historical experience, market data, and all other available information.
Contractual Obligations, Commercial Commitments and Off-Balance Sheet
---------------------------------------------------------------------
Arrangements
------------
The following table summarizes the Company's gross contractual
obligations at June 30, 2004 and the maturity periods and the effect that such
obligations are expected to have on its liquidity and cash flows in future
periods:
PAYMENTS DUE BY PERIOD
-------------------------------------------------------------
LESS THAN 2 - 3 4 - 5 MORE THAN
CONTRACTUAL OBLIGATIONS TOTAL 1 YEAR YEARS YEARS 5 YEARS
--------------------------------- ---------- ---------- ---------- ---------- ---------
PURCHASE OBLIGATIONS $2,746,000 $2,609,000 $ 137,000 $ -- $ --
CAPITAL LEASES:
Unrelated party capital lease $1,151,000 $ 437,000 $ 714,000 $ -- $ --
Related party capital lease 3,533,000 683,000 1,748,000 1,102,000 --
OPERATING LEASES:
Unrelated party operating leases $ 260,000 $ 123,000 $ 83,000 $ 45,000 $ 9,000
Related party operating lease 1,510,000 1,021,000 489,000 -- --
17
Purchase obligations include all open purchase orders outstanding
regardless of whether they are cancelable or not.
Capital lease obligations outlined above include both the principal and
interest components of these contractual obligations. Included in the related
party operating lease is the accrued lease obligation in the amount of $722,067.
On October 8, 1999, the Company entered into an Agreement with BP Solarex
("BPS") in which BPS agreed to purchase certain production equipment built by
the Company, for use in the Company's Chicago factory ("Spire Solar Chicago")
and in return the Company agreed to purchase solar cells of a minimum of two
megawatts per year over a five-year term for a fixed fee from BPS (the "Purchase
Commitment"). BPS has the right to reclaim the equipment should the Company not
meet its obligations in the Purchase Commitment. The proceeds from the sale of
the production equipment purchased by BPS have been classified as an unearned
purchase discount in the accompanying unaudited condensed consolidated balance
sheet. The Company will amortize this discount as a reduction to cost of sales
as it purchases solar cells from BPS. During the quarter ended September 30,
2003, the Company and BPS retroactively amended the agreement to include all
purchases of solar modules, solar systems, inverter systems and other system
equipment purchased by the Company from BPS in the purchase commitment
calculation. Amortization of the purchase discount amounted to $73,901 for the
six months ended June 30, 2004.
In addition, the agreement contains a put option for BPS to have the
Company create a separate legal entity for Spire Solar Chicago and for BPS to
convert the value of the equipment and additional costs, as defined, into equity
of the new legal entity. The percentage ownership in the joint venture would be
determined based on the cumulative investments by BPS and the Company.
The amended agreement also allows the Company to terminate the agreement
on 30 days notice in consideration for a termination payment based on the
aggregate amount of Spire purchases of BPS products and the fair market value of
the production equipment purchased by BPS at the time of the termination
election. As of June 30, 2004, the Company has no intention of terminating the
agreement.
In October 2002, the Company sold an exclusive patent license for a
hemodialysis split-tip catheter to Bard Access Systems, Inc. ("Bard"), a wholly
owned subsidiary of C. R. Bard, Inc., in exchange for $5,000,000 upon the
execution of the agreement, with another $5,000,000 due upon the earlier to
occur of: (a) the date of the first commercial sale of a licensed product by
Bard; or (b) no more than 18 months after signing. The agreement further
provided for two additional contingent cash payments of $3,000,000 each upon the
completion of certain milestones by Bard in 2004 and 2005. Bard has the right to
cancel the agreement at any time subsequent to the second payment. There can be
no assurances that these milestones will be attained and attainment is beyond
the control of the Company. During the year ended December 31, 2002, the Company
recorded the initial payment under the agreement, resulting in a gain of
$4,464,929, net of direct costs. Due to the potential length of time between the
first and second payments and the cancellation provisions within the agreement,
the Company did not record the potential remaining payments at that time. During
June 2003, in accordance with the agreement, the Company received notification
from Bard of the first commercial sale, collected the $5,000,000 payment due and
recorded a gain of $4,989,150, net of direct costs. During June 2004, the
Company received the first contingent milestone payment and recorded a gain of
$3,000,000. There were no direct costs associated with this payment.
Outstanding letters of credit totaled $671,000 at June 30, 2004. The
letters of credit principally secure performance obligations, and allow holders
to draw funds up to the face amount of the letter of credit if the Company does
not perform as contractually required. These letters of credit expire in
December 2004 and are 100% secured by cash.
During the second quarter of 2004, the Company entered into a Purchase
and Sale Agreement (the "Agreement") to supply certain solar systems units and
equipment to a third party. Performance under the Agreement is subject to
several precedent conditions including the issuance of a Standby Letter of
Credit by the Company in favor of the third party and the advance funding of the
total purchase price by the third party to Spire. On July 1, 2004, Spire issued
a $5,860,249 Standby Letter of Credit, as amended, in accordance with the terms
of this Agreement. The Standby Letter of Credit is subject to the terms of the
Company's Loan Agreement as discussed in Note 9 and is only available for
drawing to the extent that payments are received by the Company from the third
party. As of August 12, 2004, no advance payments have been received. The
Standby Letter of Credit automatically terminates if payment is not received by
August 31, 2004.
18
ITEM 3. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
------------------------------------------------
As required by Rule 13a-15 under the Securities Exchange Act of 1934, as
amended (the "Exchange Act"), the Company carried out an evaluation under the
supervision and with the participation of the Company's management, including
the Chief Executive Officer and President and the Chief Financial Officer, of
the effectiveness of the Company's disclosure controls and procedures as of June
30, 2004. In designing and evaluating the Company's disclosure controls and
procedures, the Company and its management recognize that there are inherent
limitations to the effectiveness of any system of disclosure controls and
procedures, including the possibility of human error and the circumvention or
overriding of the controls and procedures. Accordingly, even effective
disclosure controls and procedures can only provide reasonable assurance of
achieving their desired control objectives. Additionally, in evaluating and
implementing possible controls and procedures, the Company's management was
required to apply its reasonable judgment. Furthermore, in the course of this
evaluation, management considered certain internal control areas, including
those discussed below, in which we have made and are continuing to make changes
to improve and enhance controls. Based upon the required evaluation, the Chief
Executive Officer and the Chief Financial Officer concluded that as of June 30,
2004 the Company's disclosure controls and procedures were effective (at the
"reasonable assurance" level mentioned above) to ensure that information
required to be disclosed by the Company in the reports it files or submits under
the Exchange Act is recorded, processed, summarized and reported within the time
periods specified in the Securities and Exchange Commission's rules and forms.
From time to time, the Company and its management have conducted and will
continue to conduct further reviews and, from time to time put in place
additional documentation, of the Company's disclosure controls and procedures,
as well as its internal control over financial reporting. The Company may from
time to time make changes aimed at enhancing their effectiveness, as well as
changes aimed at ensuring that the Company's systems evolve with, and meet the
needs of, the Company's business. These changes may include changes necessary or
desirable to address recommendations of the Company's management, its counsel
and/or its independent auditors, including any recommendations of its
independent auditors arising out of their audits and reviews of the Company's
financial statements. These changes may include changes to the Company's own
systems, as well as to the systems of businesses that the Company has acquired
or that the Company may acquire in the future and will, if made, be intended to
enhance the effectiveness of the Company's controls and procedures. The Company
is also continually striving to improve its management and operational
efficiency and the Company expects that its efforts in that regard will from
time to time directly or indirectly affect the Company's disclosure controls and
procedures, as well as the Company's internal control over financial reporting.
As disclosed in our annual report on Form 10-KSB for the year ended
December 31, 2003, the Company's independent auditor, Vitale, Caturano and
Company, Ltd. ("VCC") advised management and the Audit Committee by a letter
dated March 18, 2004 that, in connection with its audit of the Company's
consolidated financial statements for the year ended December 31, 2003, it noted
certain matters involving internal control and its operation that it considered
to be a material weakness under standards established by the American Institute
of Certified Public Accountants. Reportable conditions are matters coming to an
independent auditors' attention that, in their judgment, relate to significant
deficiencies in the design or operation of internal control and could adversely
affect the organization's ability to record, process, summarize, and report
financial data consistent with the assertions of management in the financial
statements. Further, a material weakness is a reportable condition in which the
design or operation of one or more internal control components does not reduce
to a relatively low level the risk that errors or fraud in amounts that would be
material in relation to the financial statements being audited may occur and not
be detected within a timely period by employees in the normal course of
performing their assigned functions. VCC advised management and the Audit
Committee that it considered the following to constitute material weaknesses in
internal control and operations: (i) the Company's failure to adequately staff
its finance group with the appropriate level of experience to effectively
control the increased level of transaction activity, address the complex
accounting matters and manage the increased financial reporting complexities
resulting from, among other things, the acquisition of Bandwidth, the
implementation of a new financial reporting system and the investigation
surrounding the filing and eventual restatement of the Company's Form 10-QSB, as
amended, for the quarter ended June 30, 2003 and (ii) the Company's current
monthly close process does not mitigate the risk that material errors could
occur in the books, records and financial statements, and does not ensure that
those errors would be detected in a timely manner by the Company's employees in
the normal course of performing their assigned functions. The matter noted in
clause (i) above was similar to the material weakness noted by our former
independent auditor (as disclosed in prior SEC filings). VCC noted that these
matters were considered by it during its audit and did not modify the opinion
expressed in its independent auditor's report dated March 18, 2004.
19
The Company is still in the process of assessing the findings of its
independent auditors. As noted above, however, the Company has made and is
continuing to make changes in its controls and procedures, including its
internal control over financial reporting, aimed at enhancing their
effectiveness and ensuring that the Company's systems evolve with, and meet the
needs of, the Company's business. As further noted above, the Company is also
continually striving to improve its management and operational efficiency and
the Company expects that its efforts in that regard will from time to time
directly or indirectly affect the Company's controls and procedures, including
its internal control over financial reporting. For example, the Company has
recently added to its accounting staff and expects to hire additional
professionals and the Company has recently completed compliance training and
will continue to arrange for additional training for its staff. On April 1,
2004, the Company hired a permanent chief financial officer with the appropriate
experience and background to manage the diverse and complex financial issues
which may arise in the Company's business. The Company is also continuing its
efforts to upgrade its information technology capabilities and has completed the
implementation of a common accounting system at all of its business units.
Changes in Internal Control Over Financial Reporting
----------------------------------------------------
There was no change in the Company's internal control over financial
reporting that occurred during the second fiscal quarter of 2004 that has
materially affected, or is reasonably likely to materially affect, the Company's
internal control over financial reporting.
PART II
OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
None.
ITEM 2. CHANGES IN SECURITIES
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
On May 19, 2004, the Company held a Special Meeting in Lieu of Annual
Meeting of Stockholders.
The number of directors was fixed at eight, leaving one vacancy, Udo
Henseler, David R. Lipinski, Mark C. Little, Roger G. Little, Michael J.
Magliochetti, Guy L. Mayer and Roger W. Redmond were elected to the Board of
Directors to hold office until the 2005 annual meeting of the stockholders. Mr.
John A. Tarello had decided not to stand for re-election. The results for
Proposal Number 1 were as follows:
SHARES SHARES VOTING AGAINST SHARES BROKER
NOMINEE VOTING FOR OR AUTHORITY WITHHELD ABSTAINING NON-VOTES
----------------------- ---------- --------------------- ---------- ---------
Udo Henseler 5,856,094 23,694 -- --
David R. Lipinski 5,856,094 23,694 -- --
Mark C. Little 5,856,094 23,694 -- --
Roger G. Little 5,856,094 23,694 -- --
Michael J. Magliochetti 5,855,594 24,194 -- --
Guy L. Mayer 5,855,594 24,194 -- --
Roger W. Redmond 5,855,594 24,194 -- --
20
Proposal Number 2 was to approve an amendment to the Company's 1996
Equity Incentive Plan to provide for automatic granting of quarterly
non-employee director options and to eliminate all references to promissory
notes and loans. The results for Proposal Number 2 were as follows:
SHARES SHARES VOTING AGAINST SHARES BROKER
VOTING FOR OR AUTHORITY WITHHELD ABSTAINING NON-VOTES
---------- --------------------- ---------- ---------
Proposal Two 3,509,678 145,786 38,349 2,185,775
ITEM 5. OTHER INFORMATION
None.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
a. Exhibits
--------
31.1 Certification of the Chairman of the Board, Chief Executive
Officer and President pursuant toss.302 of the Sarbanes-Oxley
Act of 2002.
31.2 Certification of the Chief Financial Officer pursuant toss.302
of the Sarbanes-Oxley Act of 2002.
32.1 Certification of the Chairman of the Board, Chief Executive
Officer and President pursuant to 18 U.S.C.ss.1350, as adopted
pursuant toss.906 of the Sarbanes-Oxley Act of 2002.
32.2 Certification of the Chief Financial Officer pursuant to 18
U.S.C.ss.1350, as adopted pursuant toss.906 of the
Sarbanes-Oxley Act of 2002.
b. Reports on Form 8-K
-------------------
There were two reports on Form 8-K filed by the Registrant in the quarter
ended June 30, 2004.
May 7, 2004, Form 8-K/A, Amendment 1, Item 2 Acquisition or Disposition
of Assets and Item 7 Financial Statements, Pro Forma Financial
Information and Exhibits: Exhibit 23.1 Consent of KPMG LLP; Exhibit 99.1
Balance Sheets of Bandwidth as of March 31, 2003 (Unaudited) and December
31, 2002 and 2001 and the related Statements of Operations and Member's
Deficit, and Cash Flows for the three months ended March 31, 2003 and
2002 (Unaudited) and years ended December 31, 2002 and 2001, with
independent auditors' report thereon; Exhibit 99.2 Unaudited Pro Forma
Combined Statements of Operations of the Company for the three months
ended March 31, 2003 and the year ended December 31, 2002, all giving pro
forma effect to the Company's acquisition of Bandwidth.
May 14, 2004, Form 8-K/A, Amendment 2, Item 4 Changes in Registrant's
Certifying Accountant and Item 7 Financial Statements, Pro Forma
Financial Information and Exhibits: Exhibit 16.1 Letter from KPMG LLP to
the Securities and Exchange Commission dated May 14, 2004.
21
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Spire Corporation
Dated: August 13, 2004 By: /s/ Roger G. Little
---------------------------
Roger G. Little
Chairman of the Board,
Chief Executive Officer
and President
Dated: August 13 2004 By: /s/ James F. Parslow
---------------------------
James F. Parslow
Chief Financial Officer
22